Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2024

Open Access 01-12-2024 | Diabetes | Research

Correlation between time in range and serum uric acid in Chinese patients with type-2 diabetes: an observational cross-sectional study

Authors: Yan Liu, Xiaoren Peng, Chunjian Qiu, Jiaqing Shao

Published in: Diabetology & Metabolic Syndrome | Issue 1/2024

Login to get access

Abstract

Background

At present, the relationship between serum uric acid and blood glucose is controversial, and even opposite conclusions have been reached. We aimed to investigate the relationship between time in range and serum uric acid and estimate the influence of serum uric acid on blood glucose fluctuations in Chinese patients with type-2 diabetes mellitus (T2DM).

Methods

A total of 458 hospitalized patients with T2DM were selected. According to the SUA level, patients were divided into four groups by quartile: Q1 (≤ 254.5 µmol/L), Q2 (254.5–306.0 µmol/L), Q3 (306.0–385.5 µmol/L) and Q4 (> 385.5 µmol/L). The differences in general data, TIR and other clinical indicators between the four groups were assessed. Multifactor regression was used to analyze the relationship between subgroups of SUA and TIR, TBR, TAR, MAGE, SD, ADRR, MODD and M value. Curve fitting was used to analyze the association between TIR and SUA and to identify the inflection point.

Results

TIR showed an overall increasing trend with increasing SUA, while HbA1c, TAR, MAGE, SD, ADRR, MODD and M value showed an overall decreasing trend with increasing SUA. Multivariate regression analysis showed that, compared with Q1, there was no correlation between SUA and TIR, TAR, ADRR, SD, or MODD in all models of Q2. In the Q3 and Q4 groups, SUA was correlated with SD, MODD, and MAGE in all models. In the Q4 group, SUA was correlated with TIR, TAR, ADRR, and the M value in all models. When SUA > 306 µmol/L (Q3 and Q4), TIR and SUA have a curve-like relationship, and the inflection point of the fitted curve was SUA = 460 mmol/L. Before the inflection point, β was 0.1, indicating that when SUA increases by 10 mmol/L, the corresponding TIR increases by 1%. After the inflection point, there was no significant difference in the correlation between TIR and SUA (P > 0.05).

Conclusions

There is a close relationship between TIR and SUA in T2DM patients, it is speculated that SUA in a certain range had a positive protective effect on blood glucose control.
Literature
2.
go back to reference Li H, Zha X, Zhu Y, Liu M, Guo R, Wen Y. An invert U-shaped curve: relationship between fasting plasma glucose and serum uric acid concentration in a large health check-up population in China. Medicine. 2016;95(16):e3456.CrossRefPubMedPubMedCentral Li H, Zha X, Zhu Y, Liu M, Guo R, Wen Y. An invert U-shaped curve: relationship between fasting plasma glucose and serum uric acid concentration in a large health check-up population in China. Medicine. 2016;95(16):e3456.CrossRefPubMedPubMedCentral
3.
go back to reference Ohlson LO, Larsson B, Bjorntorp P, et al. Risk factors for type 2 (non-insulin-dependent) diabetes mellitus thirteen and one-half years of follow-up of the participants in a study of Swedish men born in1913. Diabetologia. 1988;31(11):798–805.CrossRefPubMed Ohlson LO, Larsson B, Bjorntorp P, et al. Risk factors for type 2 (non-insulin-dependent) diabetes mellitus thirteen and one-half years of follow-up of the participants in a study of Swedish men born in1913. Diabetologia. 1988;31(11):798–805.CrossRefPubMed
4.
go back to reference Cook DG, Shaper AG, Thelle DS, et al. Serum uric acid, serum glucose and diabetes: relationships in a population study. Postgrad Med J. 1986;62(733):1001–6.CrossRefPubMedPubMedCentral Cook DG, Shaper AG, Thelle DS, et al. Serum uric acid, serum glucose and diabetes: relationships in a population study. Postgrad Med J. 1986;62(733):1001–6.CrossRefPubMedPubMedCentral
6.
go back to reference Herman JB, Keynan A. Hyperglycemia and uric acid. Isr J Med. 1969;5(5):1048–52. Herman JB, Keynan A. Hyperglycemia and uric acid. Isr J Med. 1969;5(5):1048–52.
8.
go back to reference Herman J, Goldbourt U. Uric acid and diabetes: observations in a population study. Lancet. 1982;320(8292):240–3.CrossRef Herman J, Goldbourt U. Uric acid and diabetes: observations in a population study. Lancet. 1982;320(8292):240–3.CrossRef
9.
go back to reference Yano K, Rhoads GG, Kagan A, Yano K, Rhoads G, Kagan A. Epidemiology of serum uric acid among 8000 Japanese-American men in Hawaii. J Chronic Dis. 1977;30(3):171–84.CrossRefPubMed Yano K, Rhoads GG, Kagan A, Yano K, Rhoads G, Kagan A. Epidemiology of serum uric acid among 8000 Japanese-American men in Hawaii. J Chronic Dis. 1977;30(3):171–84.CrossRefPubMed
10.
go back to reference Tuomilehto J, et al. Plasma uric acid level and its association with diabetes mellitus and some biologic parameters in a biracial population of Fiji. Am J Epidemiol. 1988;127(2):321–36.CrossRefPubMed Tuomilehto J, et al. Plasma uric acid level and its association with diabetes mellitus and some biologic parameters in a biracial population of Fiji. Am J Epidemiol. 1988;127(2):321–36.CrossRefPubMed
11.
go back to reference Ling Y, Li XM, Gu Q, et al. Correlation of serum uric acid and islet beta cell functions in female type 2 diabetics. Natl Med J China. 2012;92(8):541–5. Ling Y, Li XM, Gu Q, et al. Correlation of serum uric acid and islet beta cell functions in female type 2 diabetics. Natl Med J China. 2012;92(8):541–5.
12.
go back to reference Hermans MP, Ahn SA, Rousseau MF. Raised natriuretic peptides, big-endothelin-land improved beta-cell function in type 2 diabetic males with hyperuricaemia. Diab Vasc Dis Res. 2009;6(3):190–3.CrossRefPubMed Hermans MP, Ahn SA, Rousseau MF. Raised natriuretic peptides, big-endothelin-land improved beta-cell function in type 2 diabetic males with hyperuricaemia. Diab Vasc Dis Res. 2009;6(3):190–3.CrossRefPubMed
14.
go back to reference Piconi L, Quagliaro L, Assaloni R, Ros RD, Maier A, et al. Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction. Diabetes Metab Res Rev. 2006;22:198–203.CrossRefPubMed Piconi L, Quagliaro L, Assaloni R, Ros RD, Maier A, et al. Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction. Diabetes Metab Res Rev. 2006;22:198–203.CrossRefPubMed
15.
go back to reference Lu J, Ma X, Shen Y, Wu Q, Wang R, et al. Time in range is reversely associated with carotid in tima-media thickness in type 2 diabetes. Diabet Technol Ther. 2019;22(2):72–8.CrossRef Lu J, Ma X, Shen Y, Wu Q, Wang R, et al. Time in range is reversely associated with carotid in tima-media thickness in type 2 diabetes. Diabet Technol Ther. 2019;22(2):72–8.CrossRef
16.
go back to reference Lu JY, Ma XJ, Zhou J, Zhang L, Mo YF, et al. Association of time in range, as associated by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. Diabet Care. 2018;41(11):2370–6.CrossRef Lu JY, Ma XJ, Zhou J, Zhang L, Mo YF, et al. Association of time in range, as associated by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. Diabet Care. 2018;41(11):2370–6.CrossRef
17.
go back to reference Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C, Li Z, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabet Care. 2019;42(3):400–5.CrossRef Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C, Li Z, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabet Care. 2019;42(3):400–5.CrossRef
18.
go back to reference Guo QY, Zang P, Xu SY, Song WJ, Zhang Z, et al. Time in range, as a novel metric of glycemic control, is reversely associated with presence of diabetic cardiovascular autonomic neuropathy independent of HbA1c in Chinese type 2 diabetes. J Diabet Res. 2020;2020:58170–4.CrossRef Guo QY, Zang P, Xu SY, Song WJ, Zhang Z, et al. Time in range, as a novel metric of glycemic control, is reversely associated with presence of diabetic cardiovascular autonomic neuropathy independent of HbA1c in Chinese type 2 diabetes. J Diabet Res. 2020;2020:58170–4.CrossRef
19.
go back to reference Edwards NL. Emerging therapies for gout. Rheum Dis Clin N Am. 2014;40(2):375–87.CrossRef Edwards NL. Emerging therapies for gout. Rheum Dis Clin N Am. 2014;40(2):375–87.CrossRef
20.
go back to reference Choi HK, Ford ES. Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels—the third national health and nutrition examination survey. Rheumatology. 2008;5:713–7.CrossRef Choi HK, Ford ES. Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels—the third national health and nutrition examination survey. Rheumatology. 2008;5:713–7.CrossRef
21.
go back to reference Yamaoka-Tojo M, Tojo T, Takahira N, et al. Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease. Cardiovasc Diabetol. 2010;9(1):17.CrossRefPubMedPubMedCentral Yamaoka-Tojo M, Tojo T, Takahira N, et al. Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease. Cardiovasc Diabetol. 2010;9(1):17.CrossRefPubMedPubMedCentral
22.
go back to reference Jing M A , Zhao L H , Xie Y , et al. Correlation of hyperuricemia with fasting C peptide and insulin resistance in T2DM patients. Chin J Diabete. 2015;1:46–9. Jing M A , Zhao L H , Xie Y , et al. Correlation of hyperuricemia with fasting C peptide and insulin resistance in T2DM patients. Chin J Diabete. 2015;1:46–9.
23.
go back to reference Lightfoot YL, Chen J, Mathews CE. Oxidative stress and beta cell dysfunction. Method Mol Biol. 2012;900:347–62.CrossRef Lightfoot YL, Chen J, Mathews CE. Oxidative stress and beta cell dysfunction. Method Mol Biol. 2012;900:347–62.CrossRef
24.
go back to reference Zhang YN, Yamamoto T, Hisatome I. Uric acid induces oxidative stress and growth inhibition by activating adenosine monophosphate-activated protein kinase and extracellular signal-regulated kinase signal pathways in pancreatic β cells. Mol Cell Endocrinol. 2013;375(1–2):89–96.CrossRefPubMed Zhang YN, Yamamoto T, Hisatome I. Uric acid induces oxidative stress and growth inhibition by activating adenosine monophosphate-activated protein kinase and extracellular signal-regulated kinase signal pathways in pancreatic β cells. Mol Cell Endocrinol. 2013;375(1–2):89–96.CrossRefPubMed
25.
go back to reference Rains JL, Jain SK. Oxidative stress, insulin signaling, and diabetes. Free Radical Biol Med. 2011;50(5):567–75.CrossRef Rains JL, Jain SK. Oxidative stress, insulin signaling, and diabetes. Free Radical Biol Med. 2011;50(5):567–75.CrossRef
26.
go back to reference Pasalic D, Marinkovic N, Feher-Turkovic D. Uric acid as one of the important factors in multifactorial disorders-facts and controversies. Biochem Med. 2012;22(1):324–8. Pasalic D, Marinkovic N, Feher-Turkovic D. Uric acid as one of the important factors in multifactorial disorders-facts and controversies. Biochem Med. 2012;22(1):324–8.
28.
go back to reference Zhu XP, Yan HM, Chang XX, et al. The value of arginine stimulation test in evaluating the first-phase insulin secretion and its guiding role for the treatment of type 2 diabetes mellitus. Chin J Clin Med. 2017;24(4):548–53.MathSciNet Zhu XP, Yan HM, Chang XX, et al. The value of arginine stimulation test in evaluating the first-phase insulin secretion and its guiding role for the treatment of type 2 diabetes mellitus. Chin J Clin Med. 2017;24(4):548–53.MathSciNet
29.
go back to reference Li SJ, Luo XM, Lu ZQ, et al. Correlation between serum uric acid levels and pancreatic β-cell function in patients with type 2 diabetes mellitus. Chin J Clin Med. 2023;30(2):251–6. Li SJ, Luo XM, Lu ZQ, et al. Correlation between serum uric acid levels and pancreatic β-cell function in patients with type 2 diabetes mellitus. Chin J Clin Med. 2023;30(2):251–6.
31.
go back to reference MendezH E, SalasP J, RuanoC L, et al. Lower uric acid linked with cognitive dysfunction in the elderly. CNS Neurol Disord Drug Target. 2015;14:564–6.CrossRef MendezH E, SalasP J, RuanoC L, et al. Lower uric acid linked with cognitive dysfunction in the elderly. CNS Neurol Disord Drug Target. 2015;14:564–6.CrossRef
32.
go back to reference Llull L, Laredo C, Renu A, et al. Uric acid therapy improves clinical outcome in women with acute ischemic stroke. Stroke. 2015;46(8):2162–7.CrossRefPubMed Llull L, Laredo C, Renu A, et al. Uric acid therapy improves clinical outcome in women with acute ischemic stroke. Stroke. 2015;46(8):2162–7.CrossRefPubMed
33.
go back to reference Ye BS, Lee WW, Ham JH, et al. Alzheimer’s Disease Neuroimaging Initiative Does serum uric acid act as a modualator of cerebrospinalfluid Alzheimer’s disease biomarker related cognitive decline? Eur J Neurol. 2016;23(5):948–57.CrossRefPubMed Ye BS, Lee WW, Ham JH, et al. Alzheimer’s Disease Neuroimaging Initiative Does serum uric acid act as a modualator of cerebrospinalfluid Alzheimer’s disease biomarker related cognitive decline? Eur J Neurol. 2016;23(5):948–57.CrossRefPubMed
34.
go back to reference Xiao-Jun M A , Tian D Y , Dong X U , et al. Effect of uric acid on the maturation and the biological function of BMDCs. Chin J Pathophysiol. 2007;1:95–8. Xiao-Jun M A , Tian D Y , Dong X U , et al. Effect of uric acid on the maturation and the biological function of BMDCs. Chin J Pathophysiol. 2007;1:95–8.
Metadata
Title
Correlation between time in range and serum uric acid in Chinese patients with type-2 diabetes: an observational cross-sectional study
Authors
Yan Liu
Xiaoren Peng
Chunjian Qiu
Jiaqing Shao
Publication date
01-12-2024
Publisher
BioMed Central
Keyword
Diabetes
Published in
Diabetology & Metabolic Syndrome / Issue 1/2024
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-024-01313-z

Other articles of this Issue 1/2024

Diabetology & Metabolic Syndrome 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.